FDA approves Ariad's Iclusig for rare leukemias

12/16/2012 | Fox Business · HealthDay News

Ariad Pharmaceuticals obtained accelerated FDA approval for Iclusig, or ponatinib, to treat patients with chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. The drug, which was cleared three months ahead of schedule, inhibits certain proteins that promote cancer cell development. Iclusig will be sold with a boxed warning on its label about the risk of blood clots and liver poisoning.

View Full Article in:

Fox Business · HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC